Evidence map›Paper›PMID 33683675›Full record

ReviewJournal of nephrology2021

A call to optimize haemodialysis vascular access care in healthcare disrupted by COVID-19 pandemic.

Carlo Basile, Carlo Lomonte, Christian Combe, Adrian Covic, Dimitrios Kirmizis, Vassilios Liakopoulos, Sandip Mitra, EUDIAL Working Group

Open access · bronzeAbstract readReview
In one paragraph

Review in Journal of nephrology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
5.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 5 countries.

Carlo BasileDivision of Nephrology, Miulli General Hospital, 70021, Acquaviva delle Fonti, Italy. basile.miulli@libero.it.ORCID http://orcid.org/0000-0001-8152-5471
Carlo LomonteDivision of Nephrology, Miulli General Hospital, 70021, Acquaviva delle Fonti, Italy.
Christian CombeService de Néphrologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.ORCID http://orcid.org/0000-0002-0360-573X
Adrian CovicNephrology Clinic, Dialysis and Renal Transplant Center - 'C.I. Parhon' University Hospital, and 'Grigore T. Popa' University of Medicine, Iasi, Romania.
Dimitrios KirmizisDepartment of Nephrology, Colchester General Hospital, Essex, UK.
Vassilios LiakopoulosDivision of Nephrology and Hypertension, 1st Department of Internal Medicine, AHEPA Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.ORCID http://orcid.org/0000-0002-7564-2724
Sandip MitraManchester Academy of Health Sciences Centre, Manchester University Hospitals Foundation Trust and University of Manchester, Oxford Road, Manchester, UK.
EUDIAL Working Group
Aristotle University of Thessaloniki · GRAssociazione Italiana Di Oncologia Medica · ITCentre Hospitalier Universitaire de Bordeaux · FRGrigore T. Popa University of Medicine and Pharmacy · ROManchester Academic Health Science Centre · GBOspedale Generale Regionale Francesco Miulli · ITUniversité de Bordeaux · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 pandemic has resulted in major disruption to the delivery of both routine and urgent healthcare needs in many institutions across the globe. Vascular access (VA) for haemodalysis (HD) is considered the patient's lifeline and its maintenance is essential for the continuation of a life saving treatment. Prior to the COVID-19 pandemic, the provision of VA for dialysis was already constrained. Throughout the pandemic, inevitably, many patients with chronic kidney disease (CKD) have not received timely intervention for VA care. This could have a detrimental impact on dialysis patient outcomes in the near future and needs to be addressed urgently. Many societies have issued prioritisation to allow rationing based on clinical risk, mainly according to estimated urgency and need for treatment. The recommendations recently proposed by the European and American Vascular Societies in the COVID-19 pandemic era regarding the triage of various vascular operations into urgent, emergent and elective are debatable. VA creation and interventions maintain the lifeline of complex HD patients, and the indication for surgery and other interventions warrants patient-specific clinical judgement and pathways. Keeping the use of central venous catheters at a minimum, with the goal of creating the right access, in the right patient, at the right time, and for the right reasons, is mandatory. These strategies may require local modifications. Risk assessments may need specific "renal pathways" to be developed rather than applying standard surgical risk stratification. In conclusion, in order to recover from the second wave of COVID-19 and prepare for further phases, the provision of the best dialysis access, including peritoneal dialysis, will require working closely with the multidisciplinary team involved in the assessment, creation, cannulation, surveillance, maintenance, and salvage of definitive access.

Indexed as

PandemicsArteriovenous Shunt, SurgicalComorbidityCOVID-19Delivery of Health CareHumansKidney Failure, ChronicRenal DialysisRisk AssessmentArteriovenous fistulaChronic kidney diseaseCOVID-19HaemodialysisVascular access

Identifiers

PMID33683675
PMCPMC7938289
OpenAlexW3134125520

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.